SIGA Technologies   Report issue

Contributed to NME For profit Phase 2 Phase 4
Founded: New York NY United States (1995)

Organization Overview

First Clinical Trial
2007
NCT00431951
First Marketed Drug
2018
tecovirimat (tpoxx)
First NDA Approval
2018
tecovirimat (tpoxx)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

SIGA Chief Scientific Officer | SIGA Technologies | SIGA TECHNOLOGIES | SIGA Technologies Chief Scientific Officer | SIGA Technologies, Inc.

Active Ingredients

Marketed Drugs (1)

tecovirimat (tpoxx) (2018 NDA)

Drugs in Phase 4 Trials (1)

tecovirimat (tpoxx) (10 trials)

Drugs in Phase 2 Trials (1)

mva-bn (JYNNEOS) (1 trial)

Indications

Approved Indications


 

Smallpox

Experimental Indications (Clinical Trials, Phases 1-4)


 

Monkeypox (Phase 1)

Smallpox (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 2